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M A J O R A R T I C L E
Factors Associated with the Development
of Opportunistic Infections in HIV-1–Infected Adults
with High CD4+ Cell Counts: A EuroSIDA Study
Daria Podlekareva,1 Amanda Mocroft,2 Ulrik B. Dragsted,1 Bruno Ledergerber,4 Marek Beniowski,5 Adriano Lazzarin,6
Jonathan Weber,3 Nathan Clumeck,7 Norbert Vetter,8 Andrew Phillips,2 and Jens D. Lundgren,1 for the EuroSIDA
study groupa
1Hvidovre University Hospital, Hvidovre, Denmark; 2Royal Free Hospital and University College London Medical School and 3St. Mary’s Hospital,
London, United Kingdom; 4University Hospital Zu¨rich, Zu¨rich, Switzerland; 5Medical University of Silesia, Chorzow, Poland; 6San Raffaele Scientific
Institute, Milan, Italy; 7Saint-Pierre Hospital, Brussels, Belgium; 8Pulmonary Center of the City of Vienna, Vienna, Austria
Background. Limited data exist on factors predicting the development of opportunistic infections (OIs) at
higher-than-expected CD4+ cell counts in human immunodeficiency virus (HIV) type 1–infected adults.
Methods. Multivariate Poisson regression models were used to determine factors related to the development
of groups of OIs above their respective traditional upper CD4+ cell count thresholds: group 1 (100 cells/mL),
OIs caused by cytomegalovirus, Mycobacterium avium complex, and Toxoplasma gondii; group 2 (200 cells/mL),
Pneumocystis pneumonia and esophageal candidiasis; and group 3 (300 cells/mL), pulmonary and extrapulmonary
tuberculosis.
Results. In groups 1, 2, and 3, 71 of 9219, 125 of 7934, and 36 of 7838 patients, respectively, developed 1
intragroup OI. The strongest predictor of an OI in groups 1 and 2 was current CD4+ cell count (for group 1,
incidence rate ratio [IRR] per 50% lower CD4+ cell count, 5.37 [95% confidence interval {CI}, 3.71–7.77]; for
group 2, 4.28 [95% CI, 2.98–6.14]). Injection drug use but not current CD4+ cell count predicted risk in group
3. Use of antiretroviral treatment was associated with a lower incidence of OIs in all groups, likely by reducing
HIV-1 RNA levels (IRR per 1-log10 copies/mL higher HIV-1 RNA levels for group 1, 1.50 [95% CI, 1.15–1.95];
for group 2, 1.68 [95% CI, 1.40–2.02]; and for group 3, 1.89 [95% CI, 1.40–2.54]).
Conclusion. Although the absolute incidence is low, the current CD4+ cell count and HIV-1 RNA level are
strong predictors of most OIs in patients with high CD4+ cell counts.
In the natural history of HIV-1 infection, opportunis-
tic infections (OIs) occur throughout a range of im-
mune function as measured by CD4+ cell count [1].
The introduction of combination antiretroviral therapy
(CART) in 1996–1997 resulted in a markedly reduced
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risk of OIs in HIV-1–infected patients at all levels of
immunodeficiency [2]. The risk of OIs is known to
decrease with decreasing immunodeficiency [1, 3]. As
a consequence, CD4+ cell count thresholds have been
identified below which the risk of clinical progression
and specific OIs is sufficiently high to warrant the in-
itiation of CART and prophylaxis for opportunistic
pathogens [4]. However, case reports and retrospective
studies have suggested that a minority of HIV-1–in-
fected patients develop OIs at higher-than-expected
CD4+ cell counts during CART, when the immune
function would appear to be only moderately compro-
mised, if at all [5, 6].
Some infections (e.g., tuberculosis [TB] [7]) can de-
velop over a wide range of CD4+ cell counts and might
also develop in persons without recognized immuno-
deficiency. Analyses of HIV-1–infected cohorts prior to
the introduction of CART suggested that patients with
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high CD4+ cell counts with clinical signs of one OI were at
excess risk of another [8]. Thus, several factors may influence
the risk of developing OIs at relatively high CD4+ cell counts.
These factors have, however, not been thoroughly investigated,
and, to our knowledge, they have not been previously reported
from large international cohort studies.
PATIENTS AND METHODS
Cohort. The EuroSIDA study is a prospective observational
study of HIV-1–infected patients from 82 centers in 28 Eu-
ropean countries, Israel, and Argentina. Details of the study
have been published elsewhere [2]. Six cohorts of patients have
been recruited to date. Information was provided on a stan-
dardized data-collection form at recruitment and at 6-month
intervals. Follow-up lasted through April 2005, and all CD4+
cell counts, plasma HIV-1 RNA levels, dates of starting and
stopping each antiretroviral drug, and information about dis-
ease-specific chemoprophylaxis and treatment were routinely
collected. Both CD4+ cell counts and HIV-1 RNA levels were
measured at median intervals of 3 months (interquartile range
[IQR], 2–4 months). Data on reasons for the initiation or dis-
continuation of disease-specific prophylaxis and adherence to
antiretroviral drugs were not collected. AIDS-defining diag-
noses were recorded, including distinct diagnoses made sub-
sequent to the initial diagnosis, using the 1993 clinical definition
of AIDS of the US Centers for Disease Control and Prevention
[9]. An extensive quality-assurance program was established
that included data quality control at the coordinating center
and monitoring visits to each site.
Patients. Three groups of patients were defined a priori
according to CD4+ cell count thresholds. Baseline was defined
as the date of the first CD4+ cell count measurement above the
predefined threshold. In group 1, patients were required to have
at least 1 CD4+ cell count of 100 cells/mL during prospective
follow-up in the EuroSIDA study. A diagnosis of cytomega-
lovirus (CMV) retinitis, Mycobacterium avium complex (MAC)
infection, or cerebral toxoplasmosis (TOXO) was defined as
the end point. In group 2, the CD4+ cell count threshold was
200 cells/mL, with an end point of Pneumocystis jirovecii pneu-
monia (PCP) or esophageal candidiasis (EC). In group 3, the
CD4+ cell count threshold was300 cells/mL, with an end point
of pulmonary or extrapulmonary TB. Patients were excluded
from their individual groups if they had no CD4+ cell counts
recorded after baseline or had been given a diagnosis of any
of the diseases that constituted the end point prior to baseline.
We defined CART as any combination of3 antiretroviral drugs
that included at least 1 protease inhibitor, 1 nonnucleoside re-
verse-transcriptase inhibitor, or abacavir.
Statistical methods. Descriptive statistics were used to de-
scribe the baseline characteristics of the patients in each group
and to describe patient characteristics at the date of diagnosis
of the relevant OI. Characteristics of interest were CD4+ cell
count, nadir of the CD4+ cell count, HIV-1 RNA (when avail-
able), previous and current antiretroviral therapy (ART), prior
AIDS diagnosis, and use of disease-specific prophylaxis. Of note
is the fact that patients could be included in 11 group.
At each CD4+ cell count measurement, follow-up since the
last CD4+ cell count was calculated; person-years of follow-up
(PYFU) accrued in 2 categories—above or below the CD4+ cell
count threshold—and OIs were categorized in the same way.
The incidence of OIs in each of the 3 groups was calculated
using the latest, or “current,” CD4+ cell count.
Multivariate Poisson regression was used to determine the
factors related to the development of the relevant OI in the 3
groups at a CD4+ cell count above the threshold level. Patients
were removed from the analyses if their CD4+ cell counts fell
below the threshold, and they were reinstated at the date when
the CD4+ cell count returned to a level above the threshold.
Therefore, events that occurred below the CD4+ cell count
threshold were not included. Only the first OI within each
group was included in the analyses. Factors included in uni-
variate models were demographic factors (date of birth, ethnic
origin, sex, country of origin, risk group, and region of Europe),
current CD4+ cell count, nadir of the CD4+ cell count (either
as a continuous or categorical variable, both of which were
included as log2-transformed variables when modeled as con-
tinuous variables), time with CD4+ cell count below the thresh-
old, starting CART, starting any ART, year of follow-up, and
prior AIDS-defining diagnosis. Factors that were significant in
univariate models ( ) were included in the multivariateP ! .1
model for the corresponding group. Factors that were not sig-
nificant in univariate analyses were added in turn to the final
model, to test whether they were confounding variables or were
related to the development of the OI. All statistical analyses
were performed using SAS software (version 9.1; SAS Institute).
RESULTS
As of spring 2005, the EuroSIDA database contained prospec-
tive follow-up data on 11,928 patients, of whom 9219 (77.3%)
were eligible for inclusion in group 1, 7934 (66.5%) were eli-
gible for inclusion in group 2, and 7838 (65.7%) were eligible
for inclusion in group 3. There were 71 cases of CMV retinitis
(19 cases), MAC infection (22 cases), and TOXO (31 cases)
during 45,555 PYFU in group 1 (1 patient was diagnosed with
both CMV retinitis and MAC infection on the same date); 125
cases of PCP (31 cases) and EC (94 cases) during 35,456 PYFU
in group 2; and 36 cases of TB (27 pulmonary and 10 extra-
pulmonary; 1 patient was diagnosed with both pulmonary and
extrapulmonary TB on the same date) during 29,828 PYFU in
group 3. The median (IQR) date of diagnosis of OIs was 2/
1997 (12/1995–1/2000) in group 1, 12/1998 (4/1996–5/2002)
in group 2, and 4/1999 (8/1997–1/2002) in group 3.
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Table 1. Baseline characteristics of EuroSIDA patients (groups 1–3)
Characteristic
Group (CD4+ cell count threshold)
1 (100 cells/mL)
(n p 9219)
2 (200 cells/mL)
(n p 7934)
3 (300 cells/mL)
(n p 7838)
All
Male 7003 (76.0) 5937 (74.8) 5958 (76.0)
Female 2216 (24.0) 1997 (25.2) 1880 (24.0)
MSM 3947 (42.8) 3338 (42.1) 3518 (44.9)
IDU 2212 (24.0) 1896 (23.9) 1741 (22.2)
Heterosexual 2446 (26.5) 2185 (27.5) 2070 (26.4)
Other risk factors 614 (6.7) 515 (6.5) 509 (6.5)
White 7921 (85.9) 6802 (85.7) 6790 (86.6)
Other race 1298 (14.1) 1132 (14.3) 1048 (13.4)
Patients with a prior diagnosis
of AIDS
Yes 2079 (22.6) 1203 (15.2) 1675 (21.4)
Receiving CART 3899 (42.3) 3309 (41.7) 3425 (43.7)
Receiving ART 3172 (34.4) 2663 (33.6) 2558 (32.6)
No ARTa 393 (4.3) 330 (4.2) 318 (4.1)
ART naive 1755 (19.0) 1632 (20.6) 1537 (19.6)
CD4+ cell count
Baseline, median (IQR), cells/mL 310 (193–447) 342 (251–470) 389 (333–495)
Nadir, median (IQR), cells/mL 187 (90–299) 210 (104–315) 200 (85–316)
HIV-1 RNA load, median (IQR), log10
copies/mL 2.70 (1.88–4.05) 2.70 (1.70–3.92) 2.62 (1.70–3.63)
Age, median (IQR), years 37.0 (31.7–44.1) 37.0 (31.7–44.2) 37.7 (32.3–44.8)
Date of first CD4+ cell count
above threshold, median (IQR) 11/97 (2/96–12/01) 3/98 (12/96–1/02) 3/99 (5/97–2/02)
NOTE. Data are no. (%), unless otherwise indicated. AIDS, CD4+ cell count, HIV-1 RNA load, and age were
defined at first CD4+ cell count above the threshold. HIV-1 RNA load data were available for 6380 patients in group
1 (69.2%), 5861 patients in group 2 (73.9%), and 6376 patients in group 3 (81.3%). HIV-1 RNA load !400 log10
copies/mL was for 2782 (43.6%), 2712 (46.3%), and 3396 (53.3%) patients, respectively. ART, antiretroviral therapy;
CART, combination antiretroviral therapy; IDU, injection drug user; IQR, interquartile range; MSM, men who have
sex with men.
a Patients started some ART (ART/CART) but were receiving no ART at baseline.
Patient characteristics and the incidence of OIs. The base-
line characteristics of patients are shown in table 1. We com-
pared baseline characteristics of patients who did and did not
develop OIs within each group (table 2). In group 1, patients
who developed CMV retinitis, MAC, or TOXO at a CD4+ cell
count of 1100 cells/mL had a significantly lower nadir of the
CD4+ cell count ( ) and earlier baseline CD4+ cellPp .0039
count ( ) than did those who did not develop an OI.P ! .0001
In group 2, injection drug users (IDUs) developed PCP or EC
significantly more often at a CD4+ cell count of 1200 cells/mL
than did persons in other exposure groups ( ). In groupPp .010
3, patients with a diagnosis of TB had a considerably higher
nadir of the CD4+ cell count than did those who did not develop
TB ( ). In all groups, patients who developed an OIPp .0006
had significantly higher HIV-1 RNA levels at baseline and were
less likely to be receiving CART than were patients who did
not develop an OI.
In all 3 groups, the incidence of OIs was significantly lower
in patients who had started CART, compared with those who
had not (for group 1, incidence rate ratio [IRR], 0.32 [95%
CI, 0.20–0.51]; ; for group 2, IRR, 0.29 [95% CI, 0.20–P ! .0001
0.41]; ; for group 3, IRR, 0.35 [95% CI, 0.19–0.70];P ! .0001
). The median CD4+ cell count over the course ofPp .0024
the entire follow-up period was significantly higher in patients
who had started CART in all groups: in group 1, 410 cells/mL
(IQR, 270–586 cells/mL) for patients who had started CART
and 355 cells/mL (IQR, 242–496 cells/mL) for those who had
not; in group 2, 456 cells/mL (IQR, 330–625 cells/mL) for pa-
tients who had started CART and 396 cells/mL (IQR, 300–531
cells/mL) for those who had not; and in group 3, 510 cells/mL
(IQR, 400–670 cells/mL) for patients who had started CART
and 459 cells/mL (IQR, 374–590 cells/mL) for those who had
not ( ).P ! .0001
Figure 1 shows the incidence of OIs in each group according
to the latest CD4+ cell count. In groups 1 and 2, there was a
clear pattern of decreasing incidence of the OIs as the current
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Figure 1. Incidence of opportunistic infections (OIs), according to the latest CD4+ cell count. CI, confidence interval; CMV, cytomegalovirus retinitis;
MAC, Mycobacterium avium complex; EC, esophageal candidiasis; PCP, Pneumocystis jirovecii pneumonia; PULM/EXPULM TB, pulmonary/extrapulmonary
tuberculosis; PYFU, person-years of follow-up; TOXO, cerebral toxoplasmosis.
CD4+ cell count increased, both above and below the threshold.
For group 3, the incidence of TB was significantly higher when
the CD4+ cell count decreased to !300 cells/mL. However, as
the current CD4+ cell count increased to above this level, there
were few changes in the incidence of TB, although a trend
toward an inverse correlation between current CD4+ cell count
and TB incidence was observed.
The median CD4+ cell count at diagnosis was 175 cells/mL
(IQR, 120–266 cells/mL) in group 1, 302 cells/mL (IQR, 251–
385 cells/mL) in group 2, and 444 cells/mL (IQR, 360–569 cells/
mL) in group 3, which is !2 times the predefined threshold.
The median time between last CD4+ cell count and the diag-
nosis of an OI in all groups was 2 months (IQR, 1–5 months).
Median HIV-1 RNA levels at the time of diagnosis were higher
in group 1 (3.88 [IQR, 3.02–4.87]) than in group 2 (3.62 [IQR,
2.45–4.69]) and in group 2 than in group 3 (3.53 [IQR, 2.30–
4.75]) (data were available for 37, 76, and 28 patients, respec-
tively). The median time between last HIV-1 RNA measurement
and the diagnosis of an OI was 1 month (IQR, 0–4 months)
in all groups.
Predictors for the development of an OI. The results of
the univariate and multivariate analyses are shown in table 3.
In the main analysis, adjustment for HIV-1 RNA level was not
performed, because this test was not routinely performed across
Europe until 1997, and including this variable would have re-
duced the power of the analyses.
In group 1, a lower CD4+ cell count was associated with a
higher risk of CMV retinitis, MAC infection, or TOXO (for a
50% lower CD4+ cell count, IRR, 5.37 [95% CI, 3.71–7.77];
). In addition, patients with any prior AIDS-definingP ! .0001
conditions had higher incidences of CMV retinitis, MAC in-
fection, or TOXO (IRR, 2.91 [95% CI, 1.74–4.85]; ).P ! .0001
Patients who had started CART had a significantly reduced
incidence of CMV retinitis, MAC infection, or TOXO (IRR,
0.47 [95% CI, 0.27–0.77]; ). After adjustment, olderPp .0025
patients had a significantly lower incidence of CMV retinitis,
MAC infection, or TOXO (per 10 years older, IRR, 0.71 [95%
CI, 0.53–0.95], ). Although patients with a longer cu-Pp .021
mulative time of CD4+ cell count below the threshold had a
significantly higher incidence of CMV retinitis, MAC infection,
or TOXO in the univariate analysis, this was not significant in
the multivariate model.
In group 2, the strongest predictive factor for the develop-
ment of an OI was current CD4+ cell count, as was seen in
group 1. Patients with a 50% lower current CD4+ cell count
had a significantly higher incidence of PCP or EC (IRR, 4.28
[95% CI, 2.98–6.14]; ). Furthermore, patients startingP ! .0001
either CART (IRR, 0.37 [95% CI, 0.26–0.54]; ) or anyP ! .0001
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Table 3. Incidence rate ratios (IRRs) for specific opportunistic infections above the given
threshold (includes only parameters significant in the univariate analysis; ).P ! .1
Risk factors
Univariate analysis Multivariate analysis
IRR (95% CI) P IRR (95% CI) P
Group 1
Age 0.76 (0.58–1.00) .048 0.71 (0.53–0.95) .021
Nadir CD4+ cell count 1.10 (0.99–1.21) .079 1.03 (0.88–1.21) .69
Time from nadir CD4+ cell count 0.73 (0.57–0.93) .011 0.79 (0.60–1.05) .091
Time with CD4+ cell count less
than threshold
1.27 (1.03–1.56) .025 0.86 (0.65–1.13) .27
Current CD4+ cell count 5.95 (4.19–8.44) !.0001 5.37 (3.71–7.77) !.0001
Prior diagnosis of AIDS 3.04 (1.90–4.85) !.0001 2.91 (1.74–4.85) !.0001
Started CART 0.32 (0.20–0.51) !.0001 0.47 (0.29–0.77) .0025
Started some ART 2.26 (1.16–4.42) .017 1.68 (0.82–3.42) .16
IDU 1.63 (0.99–2.70) .056 1.16 (0.69–1.94) .58
Group 2
Current CD4+ cell count 4.64 (3.26–6.61) !.0001 4.28 (2.98–6.14) !.0001
Started CART 0.29 (0.20–0.41) !.0001 0.37 (0.26–0.54) !.0001
Started some ART 0.71 (0.49–1.02) .064 0.61 (0.42–0.88) .0092
IDU 1.92 (1.33–2.79) .0006 1.51 (1.04–2.21) .031
From Eastern Europe 3.12 (1.38–7.09) .0065 1.98 (0.83–4.73) .13
Group 3
Nadir of the CD4+ cell count 0.66 (0.48–0.91) .011 0.83 (0.60–1.16) .29
Time from nadir of the CD4+
cell count
0.65 (0.47–0.90) .0096 0.78 (0.57–1.07) .12
Time with CD4+ cell count less
than threshold
0.77 (0.59–1.00) .046 0.91 (0.68–1.21) .50
Started CART 0.36 (0.19–0.70) .0024 0.49 (0.25–0.96) .037
IDU 2.38 (1.21–4.70) .012 2.12 (1.07–4.21) .032
NOTE. Age, per 10 years older; nadir and current CD4+ cell count, per 50% lower; time from nadir and
with CD4+ cell count less than threshold, per 12 months. ART, antiretroviral therapy; CART, combination
antiretroviral therapy; CI, confidence interval; IDU, injection drug user.
ART (IRR, 0.61 [95% CI, 0.42–0.88]; ) had a sig-Pp .0092
nificantly reduced incidence of PCP or EC. The incidence of
PCP or EC was 1.51 times higher in IDUs than in non-IDUs
(95% CI, 1.04–2.21; ). Further analysis showed thatPp .031
the increased incidence of PCP or EC in IDUs was mainly due
to an increased incidence of EC rather than of PCP (data not
shown).
In the multivariate model for group 3, the only predictors
for the development of TB were starting CART and HIV-1 risk
group; patients starting CART (IRR, 0.49 [95% CI, 0.25–0.96];
) had a significantly reduced incidence of TB, andPp .037
IDUs had a significantly higher incidence of TB, compared with
non-IDUs (IRR, 2.12 [95% CI, 1.07–4.21]; ).Pp .032
For the subset of patients with HIV-1 RNA levels available,
subanalyses were performed to investigate whether the inci-
dence of OIs was related to current HIV-1 RNA level after
adjustment for the same variables presented in table 3. In all
groups, a 1-log higher current HIV-1 RNA load was associated
with an increased incidence of disease (for group 1, IRR, 1.50
[95% CI, 1.15–1.95]; ; for group 2, IRR, 1.68 [95%Pp .0025
CI, 1.40–2.02]; ; for group 3, IRR, 1.89 [95% CI, 1.40–P ! .0001
2.54]; ). After adjustment for current HIV-1 RNAP ! .0001
level, there was no longer a reduced incidence of any of the
OIs associated with starting CART in groups 1–3 (for group
1, IRR, 1.27 [95% CI, 0.59–1.73]; ; for group 2, IRR,Pp .54
1.25 [95% CI, 0.75–2.08]; ; for group 3, IRR, 1.04 [95%Pp .38
CI, 0.46–2.35]; ). Additional adjustment for weight, inPp .93
a further reduced subset of patients, showed no relationship
between current weight and the development of OIs in groups
1 and 2. In group 3, after adjustment for the variables shown
in table 3 and current HIV-1 RNA load, a 5-kg weight loss was
associated with a 20% increased incidence of TB (IRR, 1.20
[95% CI, 1.01–1.43]; ).Pp .044
DISCUSSION
The results of the present study show that current CD4+ cell
count was the strongest predictor of the development of OIs
at higher-than-expected CD4+ cell counts in patients with mod-
erately to severely impaired immune function, as measured by
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CD4+ cell count (groups 1 and 2). Furthermore, we found a
strong inverse correlation between the use of CART and the
development of OIs at higher-than-expected CD4+ cell counts
that was independent of current CD4+ cell count. In group 3,
patients infected via injection drug use had an increased risk
of TB. Neither nadir nor baseline CD4+ cell counts nor the
duration of severe immunodeficiency predicted the develop-
ment of OIs in multivariate analyses.
To the best of our knowledge, this is the first study of the
risk of OIs at higher-than-expected CD4+ cell counts, and the
analyses suggest that the risk of OI is a continuum of pro-
gressively lower risk the higher the CD4+ cell count gets—
similar to the situation in patients with CD4+ cell counts within
the expected range (figure 1) [10–12]. Although this continuum
exists for all OIs, the differences in risk according to latest CD4+
cell count was less pronounced for TB than for the other OIs
studied. The explanation for this difference could be that con-
traction of TB is more dependent on exposure group than on
immunological status in patients who do not have severely
impaired immune function. This is consistent with previous
findings that IDUs develop TB more frequently than do persons
in other exposure groups [13, 14].
The CD4+ cell count thresholds chosen for groups 1–3 were
all above the 75th percentile for development of the different
OIs as identified in a study by Mocroft et al. [1]. OIs were grouped
according to the range of CD4+ cell count at which the risk of
occurrence is highest and the initiation of the disease-specific
prophylaxis is recommended at the same CD4+ cell count level
within each of the groups (except for TB, for which guidelines
do not suggest a certain CD4+ cell count threshold) [4].
Our results show a beneficial effect of CART on the incidence
of OIs at higher-than-expected CD4+ cell counts after control-
ling for the beneficial effect of CART on the number of CD4+
cells. These results are consistent with those of other studies,
which showed that the beneficial effects of CART on reducing
mortality and morbidity among HIV-1–infected patients can-
not be fully explained by how this medication affects the num-
ber of CD4+ cells [2, 15–17]. The fact that some patients de-
veloped OIs after starting CART suggests that, despite the
restoration of CD4+ cell counts, there remains a deficit in im-
mune function that cannot be captured by the level of CD4+
cells alone. However, the positive effect of CART was eliminated
after adjustment for HIV-1 RNA level, which suggests that the
decreased incidence of OIs after the initiation of CART can be
further explained by decreasing HIV-1 RNA load.
One of the study limitations, however, was that a limited
number of patients received CART, and there was not sufficient
power to repeat the analyses only for patients who started CART.
There was no correlation between the calendar date of diagnosis
of an OI in any group and the CD4+ cell count at diagnosis
(data not shown), which suggests that the OIs diagnosed in
each group after the widespread introduction of CART were
not diagnosed at different levels of immunodeficiency. Longer
prospective follow-up and a larger sample size are required to
compare the risk of disease progression in treated and untreated
patients at the same levels of CD4+ cells and with suppressed
or unsuppressed HIV-1 RNA. The limited power and difficulties
in diagnosis [18] also meant that it was not possible to evaluate
the number of events in which immune reconstitution syn-
drome played a significant role in patients starting CART. An-
other limitation is that included centers are generally centers
of excellence, and the cohort might not be representative of all
HIV-1–infected adults in Europe, especially in Eastern Europe.
Patients enrolled in the cohort are assumed to be more com-
pliant to therapy than the general population. Thus, it is likely
that we are underestimating the incidence of OIs at higher than
expected CD4+ cell counts, particularly that of TB in IDUs.
Furthermore, we have no data on current drug use, which may
be an important surrogate for a lifestyle in which the risk of
contracting TB is high.
Previously, a EuroSIDA study [19] and a study by Law et al.
[5] reported a clear trend of increasing CD4+ cell counts at the
time of AIDS diagnosis over time from before to after the
initiation of CART, although these analyses did not suggest that
the increase was due to an increasing risk of a particular OI
for a given CD4+ cell count [19]. However, few studies have
investigated factors associated with the development of OIs at
higher-than-expected CD4+ cell counts. In a EuroSIDA study
by Miller et al. [20], there was an association between disease
progression (to AIDS or death) and nadir of the CD4+ cell
count among patients with baseline CD4+ cell counts of 200
cells/mL. In that analysis, a time-updated (current) CD4+ cell
count was not included. In contrast, our analysis did not dem-
onstrate an association between the degree of previous im-
munosuppression and the risk of developing an OI.
In a nested case-control study, Hennessey et al. [21] inves-
tigated the development of AIDS at CD4+ cell counts of 1300
cells/mL. That study showed that, during the pre-CART era, the
HIV-1 RNA level prior to a diagnosis of AIDS was significantly
associated with a faster rate of disease progression, whereas no
association was observed for immunological factors. The sam-
ple size in the study, however, was small (33 cases of AIDS,
52% of which were defined by the presence of Kaposi sarcoma).
In our study, a clinically more-relevant analytic approach was
used in a larger sample (232 OIs), with considerably longer
prospective follow-up.
In summary, the present results provide important clinical
information about the risk of OIs at higher-than-expected CD4+
cell counts. The incidence of OIs, particularly in groups 1 and
2, continued to decrease the further the CD4+ cell count in-
creased from the threshold value. Thus, although OIs in groups
1 and 2 occurred infrequently at higher-than-expected CD4+
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cell counts, the incidence was considerably smaller in patients
whose current CD4+ cell count was twice that of the threshold
level. In group 3, our results suggest that TB may be present
in a person with a history of injection drug use and with clinical
symptoms suggestive of TB.
Our data may be used as an argument in favor of the initiation
and/or optimization of CART at higher CD4+ cell counts. How-
ever, it needs to be recognized that the decision of when to start
CART should be based on a complex set of arguments, including
potential benefits versus potential harm for earlier rather than
deferred initiation. Further investigation and a better understand-
ing of the factors associated with disease progression in patients
with acceptable immune function will improve the management
of HIV-1–infected patients with respect to the early recognition
of OIs, the possible use of OI prophylaxis, and the use of CART,
all of which may help to further reduce morbidity and mortality
caused by chronic HIV-1 infection.
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